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Abstract 
Background: Following the scale-up of intervention efforts, malaria burden has decreased dramatically in Solomon 
Islands (SI). Submicroscopic and asymptomatic Plasmodium vivax infections are now the major challenge for malaria 
elimination in this country. Since children have higher risk of contracting malaria, this study investigated the dynamics 
of Plasmodium spp. infections among children including the associated risk factors of residual P. vivax burden.
Methods: An observational cohort study was conducted among 860 children aged 0.5–12 years in Ngella (Central 
Islands Province, SI). Children were monitored by active and passive surveillances for Plasmodium spp. infections 
and illness. Parasites were detected by quantitative real-time PCR (qPCR) and genotyped. Comprehensive statistical 
analyses of P. vivax infection prevalence, molecular force of blood stage infection (molFOB) and infection density were 
conducted.
Results: Plasmodium vivax infections were common (overall prevalence: 11.9%), whereas Plasmodium falciparum 
infections were rare (0.3%) but persistent. Although children acquire an average of 1.1 genetically distinct P. vivax 
blood-stage infections per year, there was significant geographic heterogeneity in the risks of P. vivax infections across 
Ngella (prevalence: 1.2–47.4%, p < 0.01; molFOB: 0.05–4.6/year, p < 0.01). Malaria incidence was low (IR: 0.05 episodes/
year-at-risk). Age and measures of high exposure were the key risk factors for P. vivax infections and disease. Malaria 
incidence and infection density decreased with age, indicating significant acquisition of immunity. G6PD deficient 
children (10.8%) that did not receive primaquine treatment had a significantly higher prevalence (aOR: 1.77, p = 0.01) 
and increased risk of acquiring new bloodstage infections (molFOB aIRR: 1.51, p = 0.03), underscoring the importance 
of anti-relapse treatment.
Conclusion: Residual malaria transmission in Ngella exhibits strong heterogeneity and is characterized by a high 
proportion of submicroscopic and asymptomatic P. vivax infections, alongside sporadic P. falciparum infections. Imple-
menting an appropriate primaquine treatment policy to prevent P. vivax relapses and specific targeting of control 
interventions to high risk areas will be required to accelerate ongoing control and elimination activities.
Keywords: Plasmodium vivax, Solomon Islands, Asymptomatic, Cohort, Heterogeneity
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  mueller@wehi.edu.au 
1 Population Health and Immunity Division, The Walter and Eliza Hall 
Institute of Medical Research, Parkville, VIC, Australia
Full list of author information is available at the end of the article
Page 2 of 15Quah et al. Malar J          (2019) 18:106 
Background
Over recent years, collaborative efforts among minis-
tries of health in malaria-endemic countries, interna-
tional communities and global funders have significantly 
decreased the transmission and clinical burden of malaria 
worldwide [1]. The decrease in transmission has resulted 
in Plasmodium spp. infections becoming more heteroge-
neous within countries, between regions, among villages 
and even within households [2–4]. The decline of clini-
cal malaria has often been linked with an increase in low 
density and afebrile Plasmodium spp. infections [5–7]. 
These low-density infections are particularly problematic 
for malaria control and elimination programmes as they 
are not detected by routine surveillance and constitute a 
silent reservoir of infections [8, 9]. Asymptomatic infec-
tions may be chronic and untreated Plasmodium falci-
parum infections can persist for 6 months or more [10]. 
Meanwhile, asymptomatic Plasmodium vivax relapses 
may account for 80% of all P. vivax blood-stage infections 
[11].
In many malaria-affected countries outside sub-Saha-
ran Africa, where both P. falciparum and P. vivax coex-
ist, a shift in species predominance from P. falciparum 
to P. vivax has been observed [6, 12]. Given its strong 
preference to invade reticulocytes [13] and the more 
rapid acquisition of clinical immunity to P. vivax [14], 
low-density, asymptomatic infections tend to constitute a 
higher proportion of P. vivax infections as compared to P. 
falciparum infections. Conventional malaria surveillance 
approaches focused on monitoring clinical cases [15–18] 
are thus poorly suited to identify and delineate pockets of 
residual P. vivax transmission [19].
Following substantial progress made in malaria con-
trol, the Solomon Islands are aiming for malaria elimina-
tion by 2030 [20]. National statistics reported a tenfold 
decrease in malaria incidence over the last two decades 
from 442/1000 population in 1992 to 40.5/1000 popula-
tion in 2015 [21]. In addition, Plasmodium spp. trans-
mission is highly heterogeneous across provinces [22, 
23], ranging from high transmission in Makira Province 
(80.6/1000 population in 2013) to low transmission in 
Isabel (5.8/1000 population in 2013), and no transmission 
in Rennell and Bellona Province [21]. Though impres-
sive, these reductions in malaria burden may be fragile 
and in the context of reduced funding for malaria con-
trol and inadequate access to services reported malaria 
cases escalated to 81.0/1000 in 2016 [24, 25]. A national 
household survey in 2015 reported that while 86% of 
households in the SI own at least one long-lasting insec-
ticide-treated net (LLIN), LLIN usage was reported 
to only be 57% [21]. In addition, the prolonged use of 
insecticides and LLINs in Solomon Islands has resulted 
in a tendency for Anopheline mosquitoes to bite more 
frequently outdoors during the early evening instead of 
biting indoors and later at night [26]. A more in-depth 
understanding of the nature and risk factors for residual 
malaria transmission is thus essential for improving the 
effectiveness of Solomon Islands’ malaria control and 
elimination programmes.
In the two provinces where pilot programmes for 
malaria elimination were conducted (Isabel and Temotu), 
an increase in the proportion of malaria caused by P. 
vivax infection were observed as the overall malaria 
incidence decreased. Furthermore, a higher proportion 
of low-density and asymptomatic infections, as well as 
increased spatial clustering of residual malaria transmis-
sion risk were observed [22, 27–29]. Less is known about 
how ongoing control has changed malaria epidemiol-
ogy in the higher transmission areas of central Solomon 
Islands. National statistics (based on light microscopic 
diagnosis) in 2012 reported that 63% of malaria cases in 
Central Islands Province were caused by P. falciparum 
while the remaining 37% of malaria cases were due to P. 
vivax infections [21, 30, 31]. However, P. vivax prevalence 
by qPCR was considerably higher than that of P. falci-
parum (13% vs. 0.14%, respectively) in a cross-sectional 
survey of 3501 local residents in Ngella, Central Islands 
Province [23]. Findings from this survey also identified 
high rates of submicroscopic and asymptomatic Plas-
modium spp. infections, and a higher risk of infections 
among children as compared to adults.
Since cross-sectional surveys only measure Plasmo-
dium spp. infection at a single time point, it is difficult to 
understand how risk factors identified in the cross-sec-
tional survey may be related to the seasonal patterns of 
Plasmodium spp. infections in Ngella. From a single-time 
point study, it is also not possible to determine incidence 
of Plasmodium spp. infection and illness. Therefore, an 
in-depth investigation on the burden of asymptomatic 
and submicroscopic Plasmodium spp. infections among 
children (6 months to 12 years of age) in Ngella was con-
ducted as part of an 11-month longitudinal, observa-
tional cohort study. In order to describe the longitudinal 
dynamics of Plasmodium spp. infections and disease, 860 
children from villages located in North Coast and Bay 
regions (previously identified with higher Plasmodium 
spp. transmission rate [23]) were followed and the inci-
dence of P. vivax infections and its associating risk factors 
were studied.
Methods
Study site
This study was conducted in Ngella, Central Islands 
Province of Solomon Islands. Ngella is located between 
Malaita (approximately 50 miles north east) and Guadal-
canal provinces (approximately 27 miles south and hosts 
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the capital city, Honiara). These provinces are connected 
to Ngella by ferry service and private boats. Their malaria 
incidences were shown to be moderate to high in 2013 
(Honiara: 69.9/1000 population; Guadalcanal: 64.0/1000 
population; Malaita: 35.9/1000 population; Central 
Islands: 55.5/1000 population) [21, 31]. Further details 
of the study site are described elsewhere [23]. A total of 
20 villages in Ngella were selected for this study (Fig. 1) 
based on: (i) higher prevalence of P. vivax infections 
as noted previously among 10 villages in Ngella [23], 
(ii) consultation with Ministry of Health officials, (iii) 
easy accessibility during high tides and stormy weather 
throughout the year, as well as (iv) number of children in 
each village.
Field study design
The study was conducted from May 2013 until April 2014 
among children aged 6 months to 12 years old. A sche-
matic overview of the cohort is presented in Additional 
file  1. After obtaining written informed consent from a 
parent or legal guardian, children were clinically exam-
ined (including weight, signs of anaemia, symptoms of 
sickness, permanent disability and chronic illness), and 
screened for glucose-6-phosphate dehydrogenase (G6PD) 
deficiency using the BinaxNOW G6PD (Alere Inc., USA) 
test kit. To assure appropriate test performance, these 
tests were stored at 4 °C and conducted on top of an ice 
bucket, in a well-aerated room (< 30  °C). Demographic 
information (including age, date of birth, sex, residency 
status, village of residency), LLIN usage, and past treat-
ment of malaria were recorded. Children that fit the 
inclusion criteria (local healthy individual aged between 
6 months and 12 years old with a normal weight that has 
given consent and completed all enrolment procedures) 
were invited to participate in the cohort study. Children 
with a chronic illness or permanent disability, living in a 
remote area and children that were not permanent resi-
dents were excluded. All eligible and consenting children 
were enrolled.
Participants were then actively followed for a period 
of 11 months at 4-weekly intervals, apart from a longer 
period (up to 6  weeks) between the 7th and 8th visit 
due to the Christmas holiday season. During each active 
case detection (ACD) visit, information on LLIN usage 
the night before by mother and child was recorded. The 
reported LLIN usage by the participants and their moth-
ers was very similar and thus was combined and averaged 
the LLIN usage data from both mother and child during 
cohort. Tympanic temperature and antimalarial treat-
ment history (from each child’s personal health book) 
were also recorded.
Any child presenting with fever (temperature ≥ 38 °C) 
or history of fever (recorded up to 2  weeks prior to 
examination) was clinically assessed by a health worker. 
If malaria was suspected, a rapid diagnostic test (RDT) 
(CareStart, Access Bio, USA) was performed. Treatment 
for malaria was given in accordance with the national 
malaria treatment guidelines: artemether–lumefan-
trine  (Coartem®) treatment for P. falciparum infections; 
 Coartem® and 14  days of primaquine (PQ; 0.25  mg/kg, 
only in G6PD normal individual) for P. vivax infections. 
Guidelines require G6PD testing prior to PQ treatment. 
Haemoglobin (Hb) was measured if a child had signs of 
anaemia (conjunctiva, hand pallor, oedema, shortness of 
breath or feeling dizzy). Children were treated according 
to diagnosis and/or, when appropriate, referred to Tulagi 
Hospital. Participants with frequent absenteeism (less 
than 6 ACD visit attendances) were excluded from fur-
ther analysis.
A capillary blood sample (approximately 250  μL) was 
collected in EDTA-Microtainer (Becton–Dickinson, NJ, 
USA) tubes from all participants. At the collection site, 
50 μL of blood were immediately transferred into 250 μL 
RNAProtect (Qiagen, Germany) RNA stabilization rea-
gent, and stored in an ice container (at approximately 
4  °C) before transportation to the centralized field labo-
ratory. Upon arrival at the centralized field laboratory 
(within 12 h of collection), samples in RNA stabilization 
reagent were frozen immediately at − 20 °C. The remain-
ing blood samples were centrifuged at 300×g for 10 min 
to separate into cellular and plasma fractions, prior to 
storage at − 20  °C. Blood smears for light microscopy 
were prepared at ACD1, ACD8 and ACD11, and exam-
ined for parasites by experienced microscopists at the 
regional malaria laboratory. Information from blood 
smears positive for Plasmodium spp. was used to identify 
infected children during the survey by the local health 
workers for anti-malarial treatment. Hb levels were 
measured at ACD1, ACD6 and ACD11. At the last visit 
(ACD11), information on participant household indoor 
residual spraying (IRS) status in the previous 12 months 
was collected.
A passive case detection (PCD) system was maintained 
throughout the study at the local health facility levels 
(Tulagi hospital, local rural health centres and aid posts). 
Participants identified by PCD were clinically assessed 
and examined for malaria by RDT. Clinical diagnosis was 
recorded, and capillary blood samples were collected 
onto filter paper (Whatman 3MM, Maidstone, UK). 
Treatment was given to children as per diagnosis of the 
attending physician.
Molecular characterization of Plasmodium spp. parasites
All collected blood cell pellets (frozen state) and fil-
ter paper blood spots (room temperature) were trans-
ported to the Walter & Eliza Hall Institute in Melbourne, 
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Fig. 1 Ngella study sites and the distribution of Plasmodium spp. infections. a Participants were recruited from 20 villages in Ngella, Central Islands 
Province. Based on qPCR detection, P. vivax infections were identified in all villages while P. falciparum were detected in 10 villages (red dot). b 
Prevalence of P. vivax infections (qPCR detection) in Ngella villages (Map created using QGIS 2.10.1)
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Australia. Total genomic DNA was isolated from all 
blood cellular fractions and filter paper blood spots 
using FavorPrep 96-Well Genomic DNA Extraction 
Kits (Favorgen Biotech Corporation, Taiwan). All DNA 
extracts were screened for P. falciparum and P. vivax 
parasites using a duplex P. falciparum/P. vivax Taqman 
qPCR targeting the 18s gene [32]. Parasite densities by 
qPCR are expressed as 18s gene copy numbers/μL.
Samples positive for parasites were genotyped using 
molecular markers msp1F3, MS2 and MS16 for P. vivax 
infections, while msp2, TA81 and Polyα were used for P. 
falciparum infections [33, 34]. The genotyped samples 
were submitted for capillary electrophoresis, followed by 
fragment analysis using GeneMapper software (Applied 
Biosystems, USA), as described previously [33].
From the genotyping data, the multiplicity of infec-
tion (MOI) and molecular force of blood-stage infection 
(molFOB) were determined [35, 36]. Briefly, molFOB is the 
observed number of new blood-stage infections, as iden-
tified by individual Plasmodium spp. genotypes, divided 
by the time-at-risk (i.e. the incidence of new blood-stage 
infections). An observed infection, as identified by a spe-
cific genotype, was considered to be ‘new’ if the same 
genotype (of any molecular marker) had not been seen in 
the two previous active or passive case detection visits. 
As such, molFOB can be determined for each study par-
ticipant or as a sum over the entire study population or 
subpopulations.
Alpha (α)‑thalassaemia genotyping
All children were genotyped for the two most common 
forms of α-thalassaemia: 3.7 kbp (α−3.7) and the 4.2 kbp 
deletions (α−4.2). A multiplex PCR reaction described 
elsewhere [37] was used and the genotypes were identi-
fied by sizing patterns on agarose gel.
Statistical analyses
Field data were double entered using a REDCap elec-
tronic data capture system. All statistical analyses were 
conducted using STATA (v.12.1, StataCorp) and were 
focused mainly on P. vivax infections as there were too 
few P. falciparum infections to conduct meaningful sta-
tistical analysis, except for the analysis of incidence of 
clinical episodes, where both P. vivax and P. falciparum 
data were used. The analyses performed were similar to 
a previously described paediatric cohort study in Papua 
New Guinea [38]. Three types of analyses were con-
ducted for P. vivax infections: (1) prevalence of infection, 
(2) incidence of new infection, and (3) infection density. 
All three analyses were done using a generalized esti-
mating equation (GEE) population-averaged model with 
the semi-robust Huber/White/sandwich estimator of 
variance. This approach was taken due to the irregular 
data structure that included missing data.
The prevalence of P. vivax infection (1) throughout the 
period of the study was analysed using logistic regression 
based on the XTLOGIT command in STATA. Only the 
ACD visits data were included in the analysis of preva-
lence as the study was estimating the prevalence at each 
visit. The incidence of new P. vivax clones acquired dur-
ing cohort (2) was assessed using a negative binomial 
regression approach based on the XTNBREG command 
in STATA [35]. New P. vivax clones acquired during PCD, 
as determined using the technique described above were 
binned into the following ACD visit interval for consist-
ency. Plasmodium vivax log-transformed infection den-
sities (3) were analysed by linear regression method using 
the XTREG command in STATA. Incidences of clinical 
malaria (both P. falciparum and P. vivax infections) were 
analysed using the Andersen and Gill model of multiple 
time failure survival [39]. Backward elimination using the 
Wald’s Chi square test for individual variables was used 
to select the best fitting models in all statistical analyses. 
Associations between risk predictors from models were 
assessed using Chi square test, Kruskal–Wallis test or 
one-way analysis of variance (ANOVA), depending on 
the variable type.
Results
Study demographics
A total of 1111 children aged 6  months to 12  years old 
from 20 villages in Ngella (Fig.  1) were enrolled during 
May 2013. Of these, data from 860 children was kept for 
analysis (Fig.  2). Among the 251 excluded children, 28 
children were excluded post-enrolment (refer to Fig.  2 
for details), 63 children withdrew from the study; and 
160 children were excluded post hoc due to inconsist-
ency in follow-up attendance. The excluded participants 
(Additional file 2) were similar in gender and age to those 
included, but due to problems with accessibility of vil-
lages a significantly higher number of children residing in 
the North Coast region were excluded as compared to the 
Bay region (p-value < 0.001). The 860 children included in 
the final analyses had a minimum of 6 ACD attendances 
(Additional file 3).
The demographic characteristics of the 860 included 
children are listed in Additional file  4. These children 
came from 469 households, had a median age at enrol-
ment of 5.6  years (IQR: 3.0–8.4  years), and were 48.4% 
female and 51.6% male. Almost all of children (99%) were 
local Ngella residents. The number of children enrolled 
from the 20 villages varied, ranging from 14 (Nata) to 
78 (Polomuhu). Each region (Bay and North Coast) was 
approximately equally represented. Mean usage of LLIN 
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was high at 88%, and 89% of households were protected 
by IRS.
During enrolment, 7.2% of children reported feeling ill. 
Based on health book records, there were 65.0% children 
with at least one previous antimalarial treatment record 
(PATR), and 35.4% of children reported having received 
antimalarial treatment less than 1 year prior to the start 
this study. Although past parasite species had not been 
recorded for these previous episodes, it was observed 
that  Coartem® was most commonly given (75.7%), while 
PQ treatment was less frequent (20.0%).
The average Hb measurements from ACD1 (June 
2013), ACD6 (November 2013) and ACD11 (April 
2014) showed that 49.8% of children were anaemic 
(Hb < 110  g/L). There were 10.8% of children diag-
nosed as G6PD-deficient, of which 63.4% were male. 
Meanwhile, 34.8% of children had at least one mutated 
α-thalassaemia gene (89.3% children with heterozygous 
polymorphisms and 10.7% children with homozygous 
polymorphisms; refer to Additional file 4), with the − α3.7 
being the dominant deletion mutation (72.8%).
Burden of Plasmodium spp. infections
A total of 8329 blood samples were collected and ana-
lysed. Based on qPCR screening, 989 P. vivax infections 
(average prevalence: 11.9%; 976 observations from ACD 
visits) and 27 P. falciparum infections (overall prevalence: 
0.32%; 26 observations were from ACD visits) were iden-
tified, six of which were mixed infections with P. vivax. 
Plasmodium falciparum infections were detected in 
children from ten villages (Fig.  1). Four of 22 children 
were positive for P. falciparum more than once. These 
observations indicate that the level of local P. falciparum 
transmission in Ngella is very low. In contrast, ongoing 
transmission of P. vivax infection was observed in Ngella 
without marked seasonality (Fig.  3). Plasmodium vivax 
infections showed pronounced clustering among chil-
dren. Only 294 children (34.2%) had one or more positive 
P. vivax blood-stage infections during follow-up (Addi-
tional file 5). This is significantly fewer than predicted if 
infections were randomly distributed among children 
(expected 68.3%, p < 0.001). Among those with detected 
infections, 181 children (21.1%) had two or more P. 
vivax infections during the follow-up (expected 31.9%, 
p < 0.001) (Additional file 5). Although there was a higher 
prevalence of G6PD deficiency among male children, 
the prevalence of P. vivax infections was similar among 
G6PD deficient individuals of both genders (13.6% vs. 
8.8% by microscopy or RDT detection, 37.3% vs. 35.3% by 
qPCR detection; Additional file 4).
Genetic diversity, MOI and molFOB
Of the P. vivax positive samples, 90% were successfully 
genotyped for msp1F3 alleles, 91% for both MS2 and 
MS16 alleles. Meanwhile, only 16 of 27 (59%) of P. falci-
parum infected samples were successfully characterized 
for msp2 genotypes, but 96% and 70% of the P. falciparum 
samples were successfully genotyped by TA81 and Polyα, 
respectively (Additional file  6). Based on the calculated 
virtual heterozygosity  (HE) of the first genotyped Plas-
modium spp. infection of each infected participant, the P. 
vivax alleles  (HE of msp1F3 = 0.78;  HE of MS2 = 0.92;  HE 
of MS16 = 0.94; and  HE of 3 markers combined = 0.98) 
were found to be more diverse than the P. falciparum 
alleles  (HE of msp2 = 0.51;  HE of TA81 = 0.50;  HE of 
Polyα = 0.24; and  HE of TA81 and Polyα markers com-
bined = 0.48) (Fig. 4).
In P. vivax infections, the MOI ranged from 1 to 3, with 
73% of infections exhibiting MOI = 1. The molFOB was 
0.62  (CI95 0.53–0.72; range 0–14.47) new P. vivax infec-
tions per child per year-at-risk by msp1F3, 0.75 by MS2 
 (CI95 0.64–0.86; range 0–9.95) and 0.72 by MS16  (CI95 
0.61–0.83; range 0–12.79). Combining all three molecu-
lar markers, the average molFOB was 1.06  (CI95 0.90–1.21, 
range 0–21.70).
Almost all identified P. falciparum infections exhibited 
MOI = 1, except for three with MOI = 2. A proportion 
of 69% of the genotyped P. falciparum clones shared the 
same 508  bp msp2 FC27 subtype allele, which was also 
Enrolment
(n = 1,111)
860 children 
included for 
analysis
Post-enrolment exclusion = 28
- incomplete enrolment information (n = 10)
- not fulfilling age requirement (n = 2) 
- not fulfilling residency requirement (n = 3)
- village remoteness and poor accessibility (n = 13)
1,083 children
in cohort
63 children withdrawn during follow-up
1,020 children
in cohort
Post-hoc exclusion = 160
- Inconsistent attendance
Fig. 2 Inclusion flowchart of children in the Solomon Islands 
observational cohort
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observed previously in the cross-sectional survey during 
the previous year [23]. For P. falciparum, the average mol-
FOB was 0.02  (CI95 0.01–0.04; range 0–2.91).
Asymptomatic and submicroscopic Plasmodium spp. 
infections
A total of 433 children had at least one febrile episode 
detected during the active follow-up (ACD) visits. Of 
these children, 73 were positive by qPCR (71 P. vivax and 
4 P. falciparum including two mixed infections). As such, 
an estimated 7.2% of P. vivax and 14.8% of P. falciparum 
infections were associated with febrile symptoms. All 
febrile P. falciparum and mixed infections but only 46% 
of P. vivax infections fulfilled the definition of clinical 
malaria based on febrile assessment and positive parasite 
detection by RDT or microscopy [40].
Among the 2250 blood films examined during the 
first (ACD1—June 2013), mid-cohort (ACD8—Janu-
ary 2015) and last visits (ACD11—April 2014), only 78 
(3.5%) blood films were parasite positive by microscopy 
(76 P. vivax, 4 P. falciparum including two mixed infec-
tions) (Additional file 7). Using these data, the proportion 
of asymptomatic and submicroscopic infections in these 
3 follow-up visits were determined: 94% (247/264) of P. 
vivax and 90% (9/10) of P. falciparum infections were 
asymptomatic, while 71% (188/264) of P. vivax and 60% 
(6/10) of P. falciparum infections were submicroscopic 
(Additional file 7).
Risk predictors for P. vivax infection
Risk factors for infection prevalence, molFOB and infec-
tion density are given in Table 1.
Plasmodium vivax infection prevalence
Prevalence of P. vivax was found to be significantly asso-
ciated with increased age, G6PD deficiency, LLIN usage, 
previous antimalarial treatment record (PATR), village of 
residence and ACD visits (Table  1). Plasmodium vivax 
prevalence also varied over time (p = 0.002) but did not 
show a clear seasonal trend (Fig. 3a and Additional file 8). 
The risk of having a P. vivax infection increased linearly 
with age among children in Ngella (adjusted odds ratio, 
aOR: 1.18,  CI95 [1.13–1.23], p < 0.001). The risk of P. vivax 
infection varied among villages (p < 0.001): Compared 
with Borohinaba, Siota was identified as having the high-
est P. vivax infections risk (aOR: 6.86,  CI95 [2.68–17.5]) 
while Ha’a and Taroniara showed the lowest risk of infec-
tions (aOR: 0.18,  CI95 [0.022–1.41] and aOR: 0.18,  CI95 
[0.050–0.62], respectively). The North Coast region of 
Ngella had a higher infection risk compared to the Bay 
region (Additional file  9). Despite this, heterogeneity of 
infection was observed; children living in Kombe (North 
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Fig. 3 Plasmodium spp. infections at ACD visits. a Prevalence of qPCR-detected P. falciparum (red curve) and P. vivax (blue curve) infections by 
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Coast region) had a much lower risk of infection (aOR: 
0.66,  CI95 [0.28–1.59]) while children living in Halavo 
(Bay region) had a relatively high risk of infection (aOR: 
3.15,  CI95 [1.50–6.64]). These differences between villages 
were stable throughout the cohort study (Additional 
file 10).
With every 10% increased of the average LLIN usage, 
there was an 11% significant decrease in odds ratio, 
thus suggesting significant protective effect against P. 
vivax infections by LLIN (aOR: 0.89,  CI95 [0.82–0.97], 
p = 0.006). Indoor residual spraying (IRS, based on data 
of 754 participants only) was associated with protection 
against P. vivax infections (OR: 0.42,  CI95 [0.272–0.650], 
p < 0.001) in univariate (Additional file  9A) but not in 
multivariate analyses.
Children with PATR within 1  year of the start of the 
cohort study showed a higher risk of P. vivax infec-
tion (aOR: 2.03,  CI95 [1.45–2.83], p < 0.001). Similarly, 
G6PD-deficient children were observed to have higher 
risk of being infected by P. vivax (aOR: 1.77,  CI95 [1.16–
2.70], p = 0.008). α-Thalassaemia mutation was found to 
increase (OR: 1.43,  CI95 [1.07–1.93], p = 0.017) the risk 
of P. vivax infections) in univariate analyses only. There 
were no significant associations between being anaemic 
(Hb < 11 g/dL) and risk of P. vivax infections (Additional 
file 9A).
Diversity of P. vivax
Diversity of P. falciparum
Note:
* First P. vivax/ P. falciparum positive infection
** First P. vivax positive infection and MOI=1 for all 3 genotyping markers
*** First P. falciparum positive infection and MOI=1 for TA81 and Poly α markers; msp2 marker was excluded as the number of samples
 that were successfully genotyped were low
*msp1F3 (n = 895)
HE = 0.78
*MS2 (n = 900)
HE = 0.92
*MS16 (n = 906)
HE = 0.94
**msp1F3-MS2-MS16 
(n = 812)
HE = 0.98
*msp2 (n = 13)
HE = 0.51
*TA81 (n = 27)
HE = 0.50
*Poly α (n = 19)
HE = 0.24
***TA81-Poly α (n = 19)
HE = 0.48
Fig. 4 Contrasting diversity of P. vivax and P. falciparum in Ngella. Allelic frequencies of P. vivax markers: msp1F3, MS2, MS16 and the combined 
msp1F3-MS2-MS16 haplotypes and P. falciparum markers: msp2, TA81, Polyα and the combined TA81-Polyα haplotypes. The number of successfully 
genotyped Plasmodium spp. isolates or combined haplotypes are shown above each respective pie chart. Each estimated expected heterozygosity 
 (HE) are given below the figure
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Acquisition of new P. vivax blood‑stage infection
Acquisition of new, genetically distinct P. vivax blood-
stage clones (i.e. molFOB) was also strongly associated 
with age, villages, visit intervals, PATR, G6PD deficiency 
and α-thalassaemia mutation (Table  1b). As for preva-
lence, the risk of acquiring new P. vivax clones increased 
linearly with age (adjusted incidence rate ratio, aIRR: 
1.21,  CI95 [1.16–1.25], p < 0.001). Likewise, there was sig-
nificant heterogeneity in risks among villages (p < 0.001). 
Risk of new P. vivax infections decreased substantially 
from third visit (reference visit) to last visit (aIRR: 0.61, 
 CI95 [0.44–0.86]), with fluctuations between visit inter-
vals (Fig. 3a). Children with PATR within 1 year preceding 
the start of the cohort study (aIRR: 1.52,  CI95 [1.16–1.98], 
p = 0.002), those with G6PD deficiency (aIRR: 1.51,  CI95 
[1.05–2.18], p = 0.026) and/or α-thalassaemia mutations 
(aIRR: 1.42,  CI95 [1.10–1.84], p = 0.007), were all more 
likely to acquire new P. vivax infections.
LLIN usage did not show any significant association 
univariately (Additional file  9B) or multivariately with 
risk of new P. vivax infections. Meanwhile, children liv-
ing in a sprayed household (based on data of 754 partici-
pants only; IRR: 0.548,  CI95 [0.37–0.82], p = 0.004) were 
protected from new P. vivax infections based on uni-
variate analysis (Additional file  9B). Anaemic children 
(IRR: 0.696,  CI95 [0.52–0.92], p = 0.012) were observed 
to have protection against new P. vivax infections based 
on univariate analysis (Additional file 9B). However after 
adjustment for age, G6PD deficiency, α-thalassaemia 
mutation, PATR, villages and visit intervals, household 
spraying and anaemic status were no longer significantly 
associated with incidence of new P. vivax infections.
Plasmodium vivax infection density
Among children with P. vivax infections detected during 
ACD visits (n = 291; Table 1c), age, PATR, molFOB, febrile 
presentation, villages and study visit intervals were signif-
icantly associated with the geometric mean density of P. 
vivax infections. The P. vivax infection density decreased 
quadratically (aCoefficient: − 0.004,  CI95 [− 0.006 to 
− 0.002], p < 0.001) with age and varied significantly 
among villages (p < 0.001). Contrary to infection risk, a 
seasonal pattern was observed for P. vivax infection den-
sity (Fig.  3b) with parasite densities significantly higher 
during the dry season (ACD1 to ACD5, June–October 
2013) as compared to the wet season (ACD6 to ACD11, 
November 2013–April 2014). Overall, parasitemia 
decreased significantly (p < 0.001) with increasing time of 
follow-up.
Children presenting with febrile illness had P. vivax 
infections with higher parasitaemia (Coefficient: 0.51, 
 CI95 [0.10–0.92], p = 0.014). Similarly, P. vivax infections 
among children with higher P. vivax exposure were also 
observed to have significantly higher parasite density 
(aCoefficient: 0.02,  CI95 [0.001–0.04], p = 0.036; per unit 
increase in molFOB). Likewise, P. vivax infected children 
with PATR within 1 year prior to the start of cohort had 
significantly higher parasite densities (aCoefficient: 0.24, 
 CI95 [0.07–0.41], p = 0.005).
Reduction of parasitaemia was observed to be sig-
nificantly associated with IRS univariately (Coefficient: 
− 0.29,  CI95 [− 0.56 to − 0.02], p = 0.035; Additional 
file 9C) and multivariately (aCoefficient: 0.91,  CI95 [− 1.37 
to − 0.45], p < 0.001; Additional file 8), though this obser-
vation is based on only the 256 infected children with 
IRS information instead of all infected children (n = 291). 
G6PD deficiency, α-thalassaemia mutation, mean LLIN 
usage and anaemia were not correlated with P. vivax 
infection density.
Malaria incidence
Due to unforeseen staffing and reporting problems, the 
quality of passive case detection was highly variable 
during follow-up. To overcome this issue, three distinct 
definitions of malaria episodes were used: (1) confirmed 
malaria episode (febrile and concurrent parasitaemia 
diagnosed by microscopy or RDT), (2) presumptive 
malaria (missing ACD morbidity and PCD records but 
documented antimalarial treatment in the child’s per-
sonal health book), and (3) potential malaria (febrile and 
positive detection of Plasmodium spp. by qPCR). Since 
the qPCR TaqMan detection method is a highly sensitive 
and more accurate as compared to RDT or light micros-
copy, all malaria species were corrected based on qPCR 
species typing to reduce the possibility of misinterpreted 
RDT results at field sites (13 misdiagnosed P. vivax infec-
tions as P. falciparum in the RDT results were identi-
fied). In Solomon Islands, only patients with RDT or 
light microscopy-confirmed malaria receive anti-malarial 
treatment. However, the infected species is not generally 
recorded in the patient’s health book. The combination of 
confirmed (Definition 1) and presumptive (Definition 2) 
malaria is thus most likely to reflect the true overall bur-
den of clinical malaria episodes reliably.
There were 36 confirmed, 97 presumptive, and 39 
potential malaria cases. P. vivax accounted for most of 
the clinical infections (94.6% in confirmed and 97.4% 
in potential malaria cases). The PATR (adjusted haz-
ard ratio, aHR: 2.23,  CI95 [1.45–3.42], p < 0.001) and the 
number of new infections acquired (molFOB: 2.31 (cube 
root-transformed),  CI95 [1.77–3.02], p < 0.001) were asso-
ciated with increased risk of confirmed and presumptive 
malaria (i.e. definitions 1 and 2), while age (aHR: 0.89, 
 CI95 [0.83–0.95], p = 0.001) decreased the risk. The same 
association of PATR and molFOB with increased risk were 
also found for confirmed cases only (Definition 1) and 
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all confirmed, presumptive and potential cases (Defini-
tion 1–3), whereas the decreased incidence with age was 
found only for the latter (Additional file 11).
Plasmodium falciparum infections
Only 27 P. falciparum infections were observed during 
the cohort. The densities of these infections vary based 
on qPCR detection, ranging from 5 to 133,000 copy 
numbers/μL, while the median of parasite densities was 
10.5 copy numbers/μL (IQR: 5–148 copy numbers/μL). 
Although the occurrence of P. falciparum was observed 
to be sporadic in Ngella, four individuals with repeated P. 
falciparum infections during follow-up visits were resid-
ing in the Bay region (two living in Halavo, and one each 
from Haleta and Bola). Of these four individuals, only 
one had a febrile episode once. Gametocyte detection by 
qPCR was not conducted but no P. falciparum gameto-
cytes were detected during the three ACD visits’ micros-
copy examinations.
Discussion
This study presents the first prospective cohort study 
focusing on Plasmodium spp. infection dynamics in Sol-
omon Islands. As recognized in earlier cross-sectional 
studies in Ngella [23], and in the pilot elimination prov-
inces in Temotu [27] and Isabel [22], most Plasmodium 
spp. infections detected from the cohort were submicro-
scopic and asymptomatic P. vivax infections. This is in 
line with the general trend of an increasing proportion of 
submicroscopic Plasmodium spp. infections as malaria 
transmission decreases [5, 7, 41]. Plasmodium falcipa-
rum infections which was previously thought to be nearly 
eliminated in Ngella [23] remained low in occurrence but 
persisted across Ngella sporadically.
The incidence of clinical malaria was low among cohort 
children and when species determination was possi-
ble, P. vivax accounted for most cases. This contrasts 
with the annual national malaria report by the National 
Vector-borne Disease Control Programme, Ministry of 
Health and Medical Sciences of Solomon Islands, which 
reported that approximately half of the malaria incidence 
in Central Islands was due to P. falciparum (49% and 47% 
of malaria cases in 2013 and 2014, respectively) [21]. 
Although information retrieval was attempted by check-
ing for clinical malaria records in the health book of all 
children, it is likely that the true burden of malaria has 
been underestimated. It is also possible that P. falcipa-
rum episodes were more common among cases treated 
at the health facilities as compared to those diagnosed 
during active case detection. However, it has been pre-
viously recognized that the accuracy of clinical malaria 
case reporting in primary health care facilities in Solo-
mon Islands is often relatively poor [42]. In addition, 
the results of this study are well in line with the changes 
observed at a remote region of Malaita, the neighbouring 
island to Ngella, where in parallel with a 91% reduction 
in all malaria cases, the proportion of clinical cases due 
to P. vivax increased from 33% in 2008 to 84% in 2013 
[43]. While further studies will be required to determine 
the relative contribution of P. falciparum and P. vivax to 
the burden of clinical malaria in Ngella, data of this study 
make it clear that the very high burden of asymptomatic, 
low-density P. vivax infections is the key challenge to 
future malaria elimination in Ngella.
Although P. vivax infections were found throughout 
the study area, a very high degree of spatial heterogene-
ity in transmission was observed among the study vil-
lages. Prevalence varied up to 40-fold (range 1.2–47.4%) 
while the molFOB varied up to 90-fold (range 0.05–4.57) 
between villages that were not more than 5–25 km apart. 
Such strong variation in malaria transmission levels at 
small geographical scales has been described before in 
both moderate to high transmission areas [44, 45] and are 
even more pronounced in low transmission settings [46, 
47]. While the exact reasons for the persistence of these 
pockets of high transmission remain to be elucidated, the 
finding has important implications for current control 
and future elimination efforts in Solomon Islands. The 
high degree of heterogeneity will require spatial-targeting 
of malaria control and elimination programmes, where 
the high-risk villages (i.e. Siota) can be both a ‘sentinel 
site’ for surveillance as well as a target for enhanced con-
trol efforts, which includes active case detection and/or 
presumptive mass drug treatment [3, 48].
Although the burden of P. vivax infections varied dur-
ing follow-up, seasonal patterns, while present, were 
modest. After a small drop in prevalence from ACD1 to 
ACD2, which was due to the fact that children with LM-
positive infections detected at baseline (n = 52) received 
antimalarial treatments, prevalence and incidence 
of infections peaked in August (i.e. ACD 3) and then 
decreased during further follow-up. This coincided with 
a significant decrease in infection densities during the 
rainy season (ACD6 to ACD11; November–April), indi-
cating that infection during the rainy season could be due 
to relapsing rather than newly acquired P. vivax infection. 
According to a previous environmental study in North-
ern Guadalcanal (west of Ngella), rainfall has a negative 
effect on Anopheles farauti larvae numbers as heavy rain-
fall flushes away the breeding soil ridges by the stream 
[49], thus explaining this somewhat surprising decrease 
in transmission levels during the rainy season. In addi-
tion to these seasonal effects, the overall declining infec-
tions could also be a result of the “healthy cohort” effect 
[50–52], as participation in an intensive cohort provides 
participants both with better access to healthcare, and 
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makes their parents or guardians more aware of the 
disease.
Despite more than two-thirds of Anopheline mosqui-
toes in Solomon Islands bites outdoor and early (before 
21.00 h) [26, 53], LLINs were still associated with a mod-
erate protective effect against P. vivax infection preva-
lence among cohort children. Distribution of LLINs 
is undertaken every 3  years as the main vector con-
trol intervention in Solomon Islands and a 1.5 people/
net ratio/population was reported for 2013 in Central 
Islands province [21, 54]. High LLIN ownership was also 
reported in a later nationwide survey (2015) with 85.9% 
of households owning at least one LLIN. However, only 
56.8% people reported sleeping under the bed net [21]. 
The reasons for not using LLINs are complex but increas-
ingly higher usage indicated that the awareness cam-
paigns conducted along with the distribution of LLIN are 
working. Although a tendency towards a reduction was 
seen in the univariate analyses, LLIN use was not asso-
ciated with significant reduction in incidence of new P. 
vivax blood-stage infections. It remains to be confirmed 
if this is a consistent effect. In Solomon Islands, IRS is 
considered to be a complementary intervention to LLINs 
[55] and only high-risk villages are selected for imple-
mentation with varying insecticide dosage [21]. Despite 
incomplete information on IRS among households, chil-
dren living in sprayed households had significantly fewer 
P. vivax infections and lower parasite densities. This 
supports the continued use of IRS not merely as a com-
plementary intervention in high risk areas but also in 
elimination areas where interruption of Plasmodium spp. 
transmission is the ultimate goal [56].
Despite relatively low levels of transmission, children in 
Ngella acquire substantial levels of clinical immunity to 
P. vivax. Although the prevalence of infections, the inci-
dence of new infections, and thus exposure (molFOB), all 
increase with age and exposure is a major risk predictor 
of clinical P. vivax malaria and parasite density, the inci-
dence of clinical P. vivax episodes itself is not only very 
low but also decreases with age as does the mean den-
sity of P. vivax infections. These observed trends are signs 
of significant natural acquisition of clinical immunity 
against P. vivax. Similarly rapid acquisition of immunity 
to P. vivax was not only observed in a high transmission 
setting in PNG, where children start acquiring immu-
nity to P. vivax in their 2nd year of life [38] and clinical 
P. vivax illness is virtually absent by age five [57], but also 
in lower transmission settings [14]. Although acquisition 
of immunity differs by endemicity settings and the exact 
rate of acquisition is unclear, the more rapid acquisition 
of immunity to P. vivax is largely due to the higher mol-
FOB [36, 58] driven by the combined burden of new and 
relapsing infections [11].
Having suffered an episode of malaria in the previous 
12  months (previous anti-malarial treatment record or 
PATR) was found to be a strong risk predictor for infec-
tion prevalence, infection density, new infection, and 
malaria incidence. A higher risk of P. vivax infection 
in children with PATR suggests that treatment policy 
for P. vivax malaria in Solomon Island is sub-optimal. 
Although primaquine radical cure is part of the Solomon 
Islands’ standard treatment guidelines, it is often not pre-
scribed due to the lack of G6PD testing and when pre-
scribed, it is taken by the patient without supervision. A 
recent analysis of > 60,000 patients in Indonesian Papua 
found that unsupervised PQ was associated with only a 
minimal reduction in the risk of clinical P. vivax recur-
rences in the next 12 months [59]. As relapse infections 
can account for 80% of P. vivax blood-stage infections 
[11, 60], the high rate of recurrent P. vivax infections in 
children with PATR underlines that PQ treatment was 
either not given or not successful in removing hypnozo-
ites from the liver, leading to future relapses. This effect 
is likely to be confounded by significant inter-individual 
heterogeneity in P. vivax infection risk as indicated by the 
high degree clustering of P. vivax infections among indi-
viduals. Having had a previous P. vivax infection is thus 
not only an indication that the child may carry further 
hypnozoites in its liver, but also indicates children with 
past exposures are significantly more likely to be exposed 
to new infectious mosquito bites in future. While molFOB 
is a marker for current exposure to P. vivax infection, 
PATR is thus also a marker of (recent) past exposure.
The important contribution of relapses to the burden 
of P. vivax is further highlighted by the observation that 
G6PD deficient children had a higher prevalence of P. 
vivax infection and increased risk of acquiring new infec-
tion. This observation conflicts with previous reports 
that G6PD deficiency confers protection against severe 
P. falciparum malaria and clinical P. vivax infections and 
P. vivax parasitaemia [61–63]. While G6PD deficiency 
may protect against high P. vivax parasitaemia and thus 
clinical disease, the higher risk among G6PD deficient 
children is more likely due to the fact that these children 
represented a group that could not be treated with PQ, 
and therefore only received blood stage treatment. This 
again underlines the importance of providing efficient 
anti-relapse treatment and the need to find alternative 
treatment or prevention strategies for G6PD-deficient 
individuals.
Observation of low P. falciparum prevalence that 
are sporadic and largely asymptomatic occurring 
throughout the study areas and follow-up period is 
intriguing. Even more so as the National Vector-borne 
Disease Control Programme [21] reports that half of 
all clinical cases in Ngella are due to P. falciparum (see 
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“Discussion” above). The observed P. falciparum in this 
cohort show low levels of genetic diversity and a large 
proportion (69%) carry the same msp2 FC27 allele as 
the five P. falciparum infections detected in the previ-
ous year’s cross-sectional survey [23]. Likewise, there 
were low genetic diversity based on TA81 and Polyα 
characterization. Together, these observations suggest 
that endemic transmission of a near-clonal P. falcipa-
rum populations may persist in Ngella, similar to that 
previously observed in elimination province Temotu 
[64]. Further in-depth analyses of P. falciparum popu-
lation genetics in Ngella and comparisons to neigh-
bouring populations, as well as a detailed assessment 
of clinical isolates compared to asymptomatic infec-
tions will be required to better understand the nature 
of residual P. falciparum transmission in Ngella. In 
particular, it will be essential to understand what pro-
portion and what infections are imported from neigh-
bouring islands, which have much higher endemicity.
Conclusions
This study has confirmed the presence of a significant 
burden of P. vivax infection and the sporadic occurrence 
of P. falciparum in Ngella, largely asymptomatic and sub-
microscopic. The Solomon Islands malaria control pro-
gramme currently relies almost entirely on vector control 
measures (such as LLINs and IRS) and management of 
clinical cases. While these approaches which have jointly 
achieved an overall 95% reduction in malaria cases in 
the last two decades remain effective, they are unlikely 
to achieve elimination of malaria transmission in Solo-
mon Islands on their own. Alternative approaches that 
are better able to identify and target these silent reservoir 
Plasmodium spp. infections will be required. Higher sen-
sitivity diagnosis tools such as loop-mediated isothermal 
amplification (LAMP) or PCR may be required to track 
these infections, and using active surveillance method 
rather than relying solely on passive surveillance method 
may be required to aid malaria elimination in Solomon 
Islands [65–67]. While active case finding and reactive 
case detection [48, 68, 69] may help with eliminating 
residual foci of P. falciparum transmission, further pro-
gress with eliminating P. vivax will crucially depend on 
attacking the hidden, hypnozoite reservoir [11]. A first 
priority would be the implementation of safe and effica-
cious PQ treatment (including G6PD testing) for all P. 
vivax infected individuals [70]. Further concerted efforts 
combining accurate identification of pockets of residual 
high transmission with focal mass drug administration 
may be required to detect and eliminate the reservoir of 
asymptomatic and submicroscopic P. vivax infections.
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